- Ozempic, Wegovy competitor emerges for weight loss drugs in Zealand Pharma Quartz
- Novo Nordisk and Eli Lilly rival soars 35% after promising weight loss drug results CNBC
- Boehringer’s Obesity Candidate Survodutide Shows Strong Potential in MASH BioSpace
- Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Yahoo Finance
- Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH Patients Investor’s Business Daily
Read More: Ozempic, Wegovy competitor emerges for weight loss drugs in Zealand Pharma –